eLeaP Introduces Integrated Risk Management Aligned to ISO 14971, Linking Mitigation Directly to Training

eLeaP QMS brings structured risk management to medical device makers, supporting ISO 14971 compliance from hazard identification to post-market surveillance.

LOUISVILLE, KY, UNITED STATES, September 14, 2026 /EINPresswire.com/ — eLeaP today announced enhanced risk management capabilities within its eLeaP QMS platform, built to support medical device and life sciences organizations working under ISO 14971, ICH Q9(R1), and FMEA methodologies. The update reflects functionality already live in eLeaP’s Risk Management module, now formally positioned as a dedicated capability for regulated manufacturers.

ISO 14971 requires medical device manufacturers to apply risk management throughout a product’s lifecycle — from initial hazard identification through post-market surveillance. In practice, many organizations manage this process in spreadsheets or standalone risk registers that are disconnected from the training records auditors expect to see as proof that identified risks were actually mitigated.

The standard’s requirements get specific about what that proof looks like. Clause 7 governs risk control: manufacturers must apply control measures in a defined priority order — inherent safety by design first, then protective measures, then safety information — and verify that each measure was actually implemented and effective before treating a risk as controlled. Clause 10, retitled “Production and Post-Production Activities” in the 2019 revision, requires an active system for collecting and reviewing safety information after a device reaches the market, rather than responding to complaints as they arrive. Both clauses depend on the same underlying evidence: proof that a control measure did what it was supposed to do, and that the people responsible for it were equipped to carry it out.

FDA’s own enforcement data reflects the stakes. Under the QMSR inspection framework that took effect in February 2026, early data covering the first quarter of activity found that management oversight and risk management integration accounted for nearly 30 percent of all citations — the largest share of any category. CAPA deficiencies remain the most frequently cited issue in medical device warning letters overall, appearing in more than 60 percent of them. In both cases, investigators describe the same pattern: a risk or corrective action was identified on paper, but the organization couldn’t produce documented evidence that anyone was trained on it.

For life sciences organizations working under ICH guidelines rather than ISO 14971 directly, the relevant framework shifted in 2023 with ICH Q9(R1), now adopted by regulators including the FDA and EMA. The revision sharpened five areas: reducing subjectivity in risk assessments, addressing product availability risks, clarifying what counts as an appropriately formal risk management process, improving risk-based decision-making, and strengthening hazard identification. The common thread across both frameworks — ISO 14971 for devices, ICH Q9(R1) for pharmaceutical and biotech quality systems — is that a risk assessment is only as credible as the evidence that its conclusions were acted on.

eLeaP’s Risk Management module addresses that disconnect directly. The platform supports customizable probability and severity matrices, generates risk priority numbers, and maintains living risk registers with real-time tracking of residual risk. Critically, when a new control measure or mitigation is identified, eLeaP automatically deploys targeted training to the personnel affected by that control — creating a documented, verifiable link between “we identified a risk” and “we trained the people responsible for controlling it.”

“Auditors expect to see proof that a mitigation actually reached the people who needed it,” said Don Weobong, President at eLeaP. “That’s the piece most risk management tools leave out. In eLeaP, the moment a control measure is added to the risk assessment, the training assignment already exists. There’s no handoff to forget.”

The module also supports Paths to Harm visualization, giving quality and risk teams a clear view of how hazards, hazardous situations, and harm connect through the risk chain — documentation that maps directly to ISO 14971’s risk management file requirements.

The Risk Management module is native to eLeaP QMS, operating as part of the same connected platform as Design & Development, Change Control, and CAPA. That gives quality teams a single system of record for risk data, with no manual re-entry between tools.

Availability

eLeaP’s ISO 14971-aligned Risk Management module is available now to medical device, pharmaceutical, and biotechnology organizations as part of the eLeaP QMS platform. Organizations can request a free demo.

About eLeaP

eLeaP is a comprehensive quality management system with enterprise learning management built into one unified platform, purpose-built for regulated industries including medical devices, pharmaceuticals, biotechnology, aerospace, automotive, and food & beverage. Unlike standalone QMS solutions, eLeaP automatically connects quality processes — documents, design & development, risk, change, events, and suppliers — to training verification, closing the compliance gap that exists when QMS and training records live apart. With 20 years of experience serving more than 1,200 regulated companies, eLeaP helps organizations achieve faster regulatory submissions and maintain continuous audit readiness. Learn more at https://quality.eleapsoftware.com

Mayra Veras
eLeaP
+1 877-624-7226
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X

Transforming Risk Management for Regulated Industries

Media gallery